scholarly journals Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Ming Yu ◽  
Yu Zhu ◽  
Lichen Teng ◽  
Jialin Cui ◽  
Yajuan Su
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Circulating Tumor Dna ◽  
Early Screening ◽  
Cell Free Dna ◽  
Diagnosis And Prognosis ◽  
Free Dna ◽  
Wide Range ◽  
Tumor Dna ◽  
Circulating Cell Free Dna

In recent years, the studies on ovarian cancer have made great progress, but the morbidity and mortality of patients with ovarian cancer are still very high. Due to the lack of effective early screening and detecting tools, 70% of ovarian cancer patients are diagnosed at an advanced stage. The overall survival rate of ovarian cancer patients treated with surgical combined with chemotherapy has not been significantly improved, and they usually relapse or resist chemotherapy. Therefore, a novel tumor marker is beneficial for the diagnosis and prognosis of patients with ovarian cancer. As the index of “liquid biopsy,” circulating cell-free DNA/circulating tumor DNA (cfDNA/ctDNA) has attracted a lot of attention. It has more remarkable advantages than traditional methods and gives a wide range of clinical applications in kinds of solid tumors. This review attempts to illuminate the important value of cfDNA/ctDNA in ovarian cancer, including diagnosis, monitoring, and prognosis. Meanwhile, we will present future directions and challenges for detection of cfDNA/ctDNA.

Potential clinical applications of circulating cell-free DNA in ovarian cancer patients

2018 ◽  
Vol 20 ◽  
Author(s):  
Ana Barbosa ◽  
Ana Peixoto ◽  
Pedro Pinto ◽  
Manuela Pinheiro ◽  
Manuel R. Teixeira
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Epigenetic Alterations ◽  
Cell Free Dna ◽  
Non Invasive ◽  
Free Dna ◽  
Potential Use ◽  
Circulating Cell Free Dna

AbstractCirculating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called ‘liquid biopsy’, as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.

scholarly journals Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer

2019 ◽  
Vol Volume 12 ◽  
pp. 11517-11530 ◽  
Author(s):  
Qian Chen ◽  
Zi-Han Zhang ◽  
Shu Wang ◽  
Jing-He Lang
Keyword(s):  
Endometrial Cancer ◽  
Circulating Tumor Dna ◽  
Cell Free Dna ◽  
Free Dna ◽  
Tumor Dna ◽  
Circulating Cell Free Dna

scholarly journals Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Guanhua Zhu ◽  
Yu A. Guo ◽  
Danliang Ho ◽  
Polly Poon ◽  
Zhong Wee Poh ◽  
...  
Keyword(s):  
Disease Progression ◽  
Cancer Patients ◽  
Circulating Tumor Dna ◽  
Specific Cell ◽  
Regulatory Regions ◽  
Cell Free Dna ◽  
Invasive Approach ◽  
Tissue Specific ◽  
Free Dna ◽  
Tumor Dna

AbstractProfiling of circulating tumor DNA (ctDNA) may offer a non-invasive approach to monitor disease progression. Here, we develop a quantitative method, exploiting local tissue-specific cell-free DNA (cfDNA) degradation patterns, that accurately estimates ctDNA burden independent of genomic aberrations. Nucleosome-dependent cfDNA degradation at promoters and first exon-intron junctions is strongly associated with differential transcriptional activity in tumors and blood. A quantitative model, based on just 6 regulatory regions, could accurately predict ctDNA levels in colorectal cancer patients. Strikingly, a model restricted to blood-specific regulatory regions could predict ctDNA levels across both colorectal and breast cancer patients. Using compact targeted sequencing (<25 kb) of predictive regions, we demonstrate how the approach could enable quantitative low-cost tracking of ctDNA dynamics and disease progression.

Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study

2020 ◽  
Vol 28 (2) ◽  
pp. 159-167
Author(s):  
Srdjan Stamenkovic ◽  
Jie Cheng ◽  
Harald Surowy ◽  
Barbara Burwinkel ◽  
Melanie Gündert
Keyword(s):  
Ovarian Cancer ◽  
Pilot Study ◽  
Cancer Patients ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

Baseline mutation profiling of circulating cell-free DNA from healthy individuals to improve the detection accuracy of circulating tumor DNA in cancers.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23057-e23057
Author(s):  
Geng Tian ◽  
Ligang Xia ◽  
Zhoufang Li ◽  
Xiaohua Li ◽  
Feiyue Xu ◽  
...  
Keyword(s):  
Genomic Dna ◽  
Circulating Tumor Dna ◽  
Clinical Diagnostics ◽  
Detection Accuracy ◽  
Healthy Individuals ◽  
Cell Free Dna ◽  
Free Dna ◽  
Tumor Dna ◽  
Mutation Profiling ◽  
Circulating Cell Free Dna

e23057 Background: Cell-free circulating tumor DNA (ctDNA) has emerged as an effective blood-based biomarker for clinical diagnostics in cancers, improving the accuracy and efficiency of cancer treatment for clinic. However, the somatic mutations originated from inheritance or normal biological metabolism in circulating cell-free DNA (cfDNA) in plasma can largely interfere with the detection of ctDNA. The baseline for ctDNA evaluation is urgently needed for accuracy identification of ctDNAs in patients. Methods: Averagely 20 ml blood samples were collected from more than 1200 individuals including healthy volunteers, lung cancer, colorectal cancer, pancreatic cancer, gastric cancer patients, etc. Genomic DNA from white blood cells and cfDNA from plasma were extracted and constructed as sequencing libraries using a panel contains 50 cancer-associated genes, respectively for each sample. Then they are subjected to ultra-deep sequencing with average depth > 40000 folds covering ~21K nucleotide regions. Results: The background somatic mutation frequencies were detected in genomic DNA and cfDNA in healthy controls. The results showed that most of mutations in cfDNA were consistent with those in genomic DNA. Using data from 1200 individuals, we generated the baseline mutation profiling of cfDNA, which was referred in the ctDNA determination in cancer samples, which significantly improved the accuracy of ctDNA detection compared with tissue biopsy. Conclusions: Our studies demonstrated the importance of sequencing both cfDNA and genomic DNA for ctDNA detection in cancers. We also determined the baseline mutation profiling of circulating cfDNA from more than 1200 healthy individuals and confirmed the value of it by comparing with DNA sequencing data in cancer tissue. Our work offers clue on how to improve the detection accuracy of circulating tumor DNA in early cancer diagnosis.

scholarly journals The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

2017 ◽  
Author(s):  
Geng Tian ◽  
Xiaohua Li ◽  
Yuancai Xie ◽  
Feiyue Xu ◽  
Dan Yu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Genomic Dna ◽  
Tumor Tissue ◽  
Circulating Tumor Dna ◽  
Driver Genes ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Tumor Dna ◽  
Circulating Cell Free Dna

BackgroundRemarkable advances for clinical diagnosis and treatment in cancers including lung cancer involve cell-free circulating tumor DNA (ctDNA) detection through next generation sequencing. However, before the sensitivity and specificity of ctDNA detection can be widely recognized, the consistency of mutations in tumor tissue and ctDNA should be evaluated. The urgency of this consistency is extremely obvious in lung cancer to which great attention has been paid to in liquid biopsy field.MethodsWe have developed an approach named systematic error correction sequencing (Sec-Seq) to improve the evaluation of sequence alterations in circulating cell-free DNA. Averagely 10 ml preoperative blood samples were collected from 30 patients containing pulmonary space occupying pathological changes by traditional clinic diagnosis. cfDNA from plasma, genomic DNA from white blood cells, and genomic DNA from solid tumor of above patients were extracted and constructed as libraries for each sample before subjected to sequencing by a panel contains 50 cancer-associated genes encompassing 29 kb by custom probe hybridization capture with average depth >40000, 7000, or 6300 folds respectively.ResultsDetection limit for mutant allele frequency in our study was 0.1%. The sequencing results were analyzed by bioinformatic expertise based on our previous studies on the baseline mutation profiling of circulating cell-free DNA and the clinicopathological data of these patients. Among all the lung cancer patients, 78% patients were predicted as positive by ctDNA sequencing when the shreshold was defined as at least one of the hotspot mutations detected in the blood (ctDNA) was also detected in tumor tissue. Pneumonia and pulmonary tuberculosis were detected as negative according to the above standard. When evaluating all hotspots in driver genes in the panel, 24% mutations detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). When evaluating all genetic variations in the panel, including all the driver genes and passenger genes, 28% detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). Positive detection rates of plasma ctDNA in stage I lung cancer patients is 85%, compared with 17% of tumor biomarkers.ConclusionWe demonstrated the importance of sequencing both circulating cell-free DNA and genomic DNA in tumor tissue for ctDNA detection in lung cancer currently. We also determined and confirmed the consistency of ctDNA and tumor tissue through NGS according to the criteria explored in our studies. Our strategy can initially distinguish the lung cancer from benign lesions of lung. Our work shows that the consistency will be benefited from the optimization in sensitivity and specificity in ctDNA detection.

Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden

2017 ◽  
Vol 26 (4) ◽  
pp. 395-401 ◽  
Author(s):  
Jagdeep Singh Bhangu ◽  
Hossein Taghizadeh ◽  
Tamara Braunschmid ◽  
Thomas Bachleitner-Hofmann ◽  
Christine Mannhalter
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Tumor Burden ◽  
Cell Free Dna ◽  
Free Dna ◽  
Potential Biomarker ◽  
Colorectal Cancer Patients ◽  
Circulating Cell Free Dna
Sign in / Sign up

Export Citation Format

Share Document